TORNA ALL’ELENCO

The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups and correlates with gut microbiota (GM) in patients with advanced renal cell carcinoma (RCC) in Journal of Clinical Oncology

2023
AOU Alessandria

Tipo pubblicazione

Conference Abstract

Autori/Collaboratori (15)Vedi tutti...

Silva CAC
Nuclear Medicine Unit, Oncology and Haematology Department, University Hospital of Modena, Modena, Italy
Zoppi S
Inserm U1015, Equipe Labelliseé - Ligue Nationale Contre Le Cancer, Gustave Roussy Cancer Campus, Villejuif, France; Department of Medicine and Surgery, University of Parma, Parma, Italy, Parma, Italy; Azienda Ospedaliera Universitaria Integrata, Verona, Verona, Italy; Department Of Cellular, Computational And Integrative Biology, Università degli Studi di Trento, Trento, Italy; Azienda Ospedaliera Ss Antonio E Biagio E Cesare Arrigo, SSD Mesotelioma, Alessandria, Italy; CHU Brugmann Brussels, Medical Oncology Department, Brussels, Belgium; Gustave Roussy, Villejuif, France; Gustave Roussy Cancer Campus, Villejuif, France; Gustave Roussy Cancer Campus Grand Paris, Villejuif, France; Medical Oncology, Gustave Roussy, Université Paris Saclay, Paris, France
Reni A
Inserm U1015, Equipe Labelliseé - Ligue Nationale Contre Le Cancer, Gustave Roussy Cancer Campus, Villejuif, France; Department of Medicine and Surgery, University of Parma, Parma, Italy, Parma, Italy; Azienda Ospedaliera Universitaria Integrata, Verona, Verona, Italy; Department Of Cellular, Computational And Integrative Biology, Università degli Studi di Trento, Trento, Italy; Azienda Ospedaliera Ss Antonio E Biagio E Cesare Arrigo, SSD Mesotelioma, Alessandria, Italy; CHU Brugmann Brussels, Medical Oncology Department, Brussels, Belgium; Gustave Roussy, Villejuif, France; Gustave Roussy Cancer Campus, Villejuif, France; Gustave Roussy Cancer Campus Grand Paris, Villejuif, France; Medical Oncology, Gustave Roussy, Université Paris Saclay, Paris, France

et alii...

Abstract

Background: The LIPI score has been reported as an independent prognostic factor in RCC patients treated with immune checkpoint inhibitors (ICI) or tyrosine kinase inhibitors (TKI). Here, we aimed to correlate LIPI score and GM composition in patients with RCC. Methods: We prospectively collected fecal samples of all comers RCC patients who started a 1st or beyond line therapy (standard or clinical trial) in the NCT0457446 at Gustave Roussy. Neutrophil to lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH) were obtained from routine blood tests. Shot gun metagenomic sequencing (MGS) data were analyzed by multivariate and pair-wise/fold ratio. Clinical benefit ratio (CBR, complete response + partial response + stable disease, RECIST1.1) and overall survival (OS, from treatment start) were evaluated. Multivariate analysis (MVA) for OS included age, gender, therapy line, IMDC, histology, hypoalbuminemia. Results: From February 2016 to July 2021, 160 patients were screened and 102 were included. Median age was 61 years (22-89), patients were mostly males (75%) and clear cell histology (90%). Patients were treated in 1st (15%), 2nd (53%) and beyond (32%) lines. Treated with ICI monotherapy (65%), followed by TKI or mTOR (20%) and ICI combination (19%). IMDC was 32% good (G), 54% intermediate (I) and 14%poor (P) and LIPI was69%G, 25%I and6%P. Median OS was 42.9, 17.7 and 8.3 months in patients with LIPI G, I and P, respectively (p<0.0001). Among IMDC risk groups, IMDC G + LIPI G had better OS compared to other subgroups (p=0.017), and those with IMDC P + LIPI P had the worse OS. Overall, LIPI G had higher rates of CBR than I+P LIPI (74% vs 50%; p=0.0158). At MVA, LIPI was independently associated with OS (HR 6.25, 2.02-24.34; p=0.0187). Overall, Parabacteroides merdae and Veillonella parvula were enriched in LIPI I+P, while LIPI G harbored Faecalibacterium prausnitzii. In patients treated with ICI monotherapy, LIPI I+P were enriched with Bacteroides spp (P. mer

DOI : 10.1200/jco.2023.41.6_suppl.719

Keywords

endogenous compound; immune checkpoint inhibitor; lactate dehydrogenase; mammalian target of rapamycin; protein tyrosine kinase inhibitor; adult; advanced cancer; Bacteroides; cancer patient; cancer prognosis; cancer survival; clinical outcome; clinical trial; commensal; conference abstract; controlled study; drug combination; drug therapy; Faecalibacterium prausnitzii; feces; female; gender; genetic susceptibility; high risk population; histology; histopathology; human; human tissue; hypoalbuminemia; intestine flora; line of treatment; lung; major clinical study; male; metagenomics; metastatic renal cell carcinoma; middle aged; monotherapy; neutrophil lymphocyte ratio; nonhuman; outcome assessment; overall survival; Parabacteroides; prospective study; renal cell carcinoma; Ruminococcaceae; Veillonella parvula;